Analyses of chlamydia trachomatis L2 in the background of the host cell proteome

Inclusion membrane proteins

Birkelund, Svend; Sennels, Lau; Christiansen, Gunna; Stensballe, Allan

Published in:
Proceedings of the Thirteenth International Symposium on Human Chlamydial Infections, ASIOMAR Conference Grounds, 22-27 June 2014, Pacific Grove, CA, USA

Publication date:
2014

Document Version
Publisher's PDF, also known as Version of record

Link to publication from Aalborg University

Citation for published version (APA):
Proceedings of the Thirteenth International Symposium on Human Chlamydial Infections

ASILOMAR Conference Grounds, Pacific Grove, California
June 22 – 27, 2014

Editors
Julius Schachter
Gerald I. Byrne
Max A. Chernesky
Ian N. Clarke
Toni Darville
Edward W. Hook, III

David C. Mabey
Jorma Paavonen
Michael Starnbach
Richard S. Stephens
Peter Timms
Priscilla Wyrick
CHLAMYDIAL INFECTIONS

Proceedings of the Thirteenth International Symposium on Human Chlamydial Infections

ASILOMAR Conference Grounds, Pacific Grove, California
June 22 – 27, 2014

Editors
Julius Schachter, University of California, San Francisco, USA
Gerald I. Byrne, University of Tennessee, USA
Max A. Chernesky, McMaster University, Canada
Ian N. Clarke, University of Southampton, UK
Toni Darville, University of North Carolina, Chapel Hill, USA
Edward W. Hook, III, University of Alabama, Birmingham, USA
David C. Mabey, London School of Hygiene & Tropical Medicine, UK
Jorma Paavonen, University of Helsinki, Finland
Michael Starnbach, Harvard University, USA
Richard S. Stephens, University of California, Berkeley, USA
Peter Timms, Queensland University of Technology, Australia
Priscilla Wyrick, University of North Carolina, Chapel Hill, USA
CHLAMYDIAL INFECTIONS

Proceedings of the Thirteenth International Symposium on Human Chlamydial Infections

2014

International Chlamydia Symposium
San Francisco, CA 94110
USA

ISBN 0-9664383-4-5
ANALYSES OF CHLAMYDIA TRACHOMATIS L2 IN THE BACKGROUND OF THE HOST CELL PROTEOME – INCLUSION MEMBRANE PROTEINS.
Svend Birkelund¹, Lau Sennels¹, Gunna Christiansen² and Allan Stensballe¹.
¹Department of Health Science and Technology, Aalborg University, Denmark
²Department of Biomedicine, Aarhus University, Denmark

Introduction
The Chlamydia trachomatis elementary body (EB) proteome has been characterized with 2D-gel electrophoresis and identification of proteins with tryptic digest and subsequent protein identification by mass-spectrometry (MS)(Shaw et al. 2002). The number of proteins that can be identified has increased after digesting complex protein samples and thereafter separating the peptides by liquid chromatography (LC) coupled MS/MS. The technique is called gel-free proteomics in contrary to 2D-gel based proteomics. Using this technique Skipp et al. (2005) identified 328 proteins in purified EB of the 889 encoded in the genome (Thomson et al. 2008). The technique has also been used to characterize the outer membrane complex of C. trachomatis L2 and to find in vivo cleavage sites of the proteins, especially between the auto-transporter and passenger domain of the polymorphic outer membrane proteins (Pmp), (Birkelund et al. 2009). Saka et al. (2011) identified 485 proteins in purified EB and reticulate bodies (RB). Due to the high quality of the data it was possible for them to quantify 373 of the proteins. Fifty-nine proteins were only found in RB, and in EB the in vivo cleavages of the Pmp proteins could confirm the results of by Birkelund et al. (2009). Saka et al. identified 13 Inclusion membrane proteins (Inc) in purified RBs and EBs. Due to the type III secretion of Inc to the inclusion membrane we expected to find additional Inc proteins by analyzing the entire infected host cell.

By combining ultra high pressure LC (UHPLC) and a mass-spectrometer with a dynamic range of $10^5$ and sub-ppm mass-accuracy, it is now possible to identify 7,093 proteins in a HeLa cell sample using MS/MS (Wiśniewski et al. 2009). Therefore, we decided to characterize expression in C. trachomatis L2 infected host cells (HeLa) after 43 hrs of infection.

Methods
Semiconfluent monolayers of HeLa cells (75 cm²) were infected with C. trachomatis L2 (434/Bu), for 30 minutes with the infectious dose of 1 IFU/cell and then incubated for 42 hrs and 30 minutes in RPMI-1640 medium containing 10% FCS and gentamicin. Medium was also changed on un-infected HeLa cells. Cells were washed 3 times in PBS, and the cells were solubilized in 5% sodium deoxycholate (SDC), 50 mM triethylammonium
bicarbonate (TEAB) and phosphatase inhibitors. The samples were heated to 90°C for 5 minutes. Filter-aided sample preparation (FASP) and digestion with trypsin was performed according to León et al. (2013) using 10 kDa spinfilters for buffer exchange. The samples were reduced with 12 mM Tris(2-carboxyethyl)phosphine hydrochloride, alkylated with 40 mM iodoacetamide and digested with trypsin (1:50). All reactions were done in 0.5% SDC and 50 mM TEAB. After digestion, formic acid was added to 0.5% and SDC was removed with ethyl acetate extraction. Samples were analyzed on a Thermo Electron QExactive mass spectrometer.

RESULTS
The trypsin-digested samples were separated with a UPLC system. The system was online coupled to a QExactive mass spectrometer. A 4-hrs UPLC (8-30%) gradient was used. The 12 highest intensity peptides were selected per second to high-energy collision dissociation (HCD) and MS² spectra were obtained. Spectra were extracted from raw files with Thermo Proteome Discoverer and searched with a Mascot server for *C. trachomatis* L2 peptides using all CHLT2 UnProtKB sequences.

![Fig. 1) MS² spectrum of a peptide ion form CTL0882](image)

In figure 1 the MS² spectrum of a fragmented peptide ion of 2350.20 Da is seen. The mass difference between the peaks is analyzed for amino acid residues masses. Since the peptide is ionized in the C-terminal part, the sequence of the peptide is TTVSETQQQQLSTIETTLGS. The peptide is from the Inc protein CTL0882 (Ct618 homolog in D). The samples were run in triplicates resulting in approximately 900.000 MS² spectra for infected HeLa cells as well as for uninfected cells. 250 *C.
**trachomatis** proteins were identified with more than 2 peptides with an expectancy score of \(<e^{-4}\) and a mowse score of \(>200\) in the mascot search program. Accession numbers for predicted Inc proteins according to Lutter et al. (2012) were searched in the output. Seven predicted Inc proteins were identified with at least 2 different unique peptides (Table 1).

### Table 1

<table>
<thead>
<tr>
<th>Accession Number</th>
<th>D homolog</th>
<th>Peptide sequence</th>
<th>Saka</th>
<th>Inc</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTL0371 INCE_CHLT2</td>
<td>CT116</td>
<td>LDNLTDVPVR, SSPANEPAVQFF</td>
<td>0</td>
<td>E</td>
</tr>
<tr>
<td>CTL0373 B0B9M6_CHLT2</td>
<td>CT118</td>
<td>VLSSVQSMPVIDK, SIGDSVGSAFDDINK, SIGDSVGSAFDDINKDNSR</td>
<td>RB</td>
<td>G</td>
</tr>
<tr>
<td>CTL0402 B0B9Q5_CHLT2</td>
<td>CT147</td>
<td>SSDATVGLQHQIR, DLIDVVEESIETAK, DLIDTILQMSAAPGGVTPLVDGVHK</td>
<td>RB/NQ</td>
<td></td>
</tr>
<tr>
<td>CTL0466 B0B9W4_CHLT2</td>
<td>CT214</td>
<td>FAAFLSLIEK, GASAPLISGQADDSLPNR</td>
<td>EB</td>
<td></td>
</tr>
<tr>
<td>CTL0476 B0B9X4_CHLT2</td>
<td>CT223</td>
<td>AHLDVCLGEK, EEISQLEQQLAK, VEANGINDLSPAPEAK</td>
<td>RB/NQ</td>
<td></td>
</tr>
<tr>
<td>CTL0480 B0B7K4_CHLT2</td>
<td>CT288</td>
<td>QYDILNAAFPNK, QLSQIDLTIQAFEK YDSINHSIEEISDR</td>
<td>RB</td>
<td></td>
</tr>
<tr>
<td>CTL0882 B0B8J3_CHLT2</td>
<td>CT618</td>
<td>LLSSATATTLR, TNPDSFHDLVSSQR, LSSVNDLFDLISSSTCLAR, TTSETQQQQLSTIETTGLSAK</td>
<td>RB</td>
<td></td>
</tr>
</tbody>
</table>

Six of the proteins were also identified in purified RB/EB by Saka et al. (2011). IncE was not found in that study. To control the specificity of our *C. trachomatis* identifications, against the human protein background, we performed a database search of the MS data on the un-infected HeLa in a Mascot search against the L2 database. Only chlamydia Glyceraldehyde-3-phosphate dehydrogenase and PolyA polymerase were unambiguously identified in the L2 database with high scores, due to the conserved peptides between the human and chlamydia proteins.

**DISCUSSION**

On unfractionated infected HeLa was it possible to identify 250 *C. trachomatis* L2 proteins with high confidence with the FASP method in combination with UHPLC and on-line MS. Saka et al. (2011) identified 426 proteins in purified EB and 269 in RB. However, the current method also gives the possibility to look at the changes in the host cell proteins and
the chlamydial proteins secreted to the host. Saka et al. (2011) found, however, many Inc proteins in their proteomics study of RB and EB even though the proteins should be secreted from the chlamydiae. This is likely due to presence of the Inc family proteins in chlamydiae before secretion. We found IncE (CT116) in additional to the Inc protein found by Saka et al.

The expression of IncE is in good agreement with Lutter et al. (2012) and Almeida et al. (2012) who showed that the *incE* gene in the LGV serovars had been under a positive selection pressure with many nonsynonymous nucleotide substitutions. This was also the case for CT118 and CT147 that we also found expressed. By quantitative PCR CT116, CT118 and CT147 mRNAs were found to be expressed early in the *C. trachomatis* L2 developmental cycle (Lutter et al. 2012). This indicates that the proteins are stable in the host cells. Therefore, the present proteomic study supports the results by Lutter et al. (2012) and Almeida et al. (2012) indicating that polymorphisms in the *Inc* genes are of importance for disease and tissue tropism.

REFERENCES


